Loading company…
NapaJen Pharma, Inc. is a pharmaceutical company developing drugs for stem cell transplantation in hematological cancers.
Founded in 2005 as Napa Jenomics Corporation and based in California, US, NapaJen Pharma, Inc. develops drugs for hematopoietic stem cell transplantation in hematological cancers. Its technology delivers oligonucleotide drugs to immune cells by binding the Dectin-1 receptor. The lead therapy, NJA-730, is in Phase 1 trials for acute graft-versus-host disease (GvHD). In March 2024 INCJ, Inc. sold its entire stake to KNC Laboratories Co., Ltd., and CEO Kenji Arima leads the company. Its funding stage is listed as Series B.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in